Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07292714

A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate Efficacy and Safety of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions Chronic Obstructive Pulmonary Disease COPD

Interventions 9MW1911 Phase II placebo

Updated 1 time since 2026 Last updated: Dec 15, 2025 Started: Jul 15, 2025 Primary completion: Dec 31, 2027 Completion: Feb 29, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07292714, this PHASE2 trial focuses on Chronic Obstructive Pulmonary Disease COPD and remains actively recruiting participants. Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

1 version recorded

Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mabwell (Shanghai) Bioscience Co., Ltd.

Data source: Mabwell (Shanghai) Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baotou, China , Beijing, China , Changsha, China , Chengdu, China , Chizhou, China , Chongqing, China , Hefei, China , Hengyang, China , Heze, China , Huizhou, China and 33 more locations